Achieving our vision of a world without T1D requires global collaboration. Approximately 1.6 million Americans live with type 1 diabetes (T1D), and countless more people are affected by the disease around the world. Our five affiliates in Australia, Canada, Israel, the Netherlands and the United Kingdom are pivotal partners in funding the research that will remove the impact of T1D from people’s lives until there is a cure.
- JDRF Australia was recognized as the Charity of the Year in The Australian Charity Awards 2014.
- Australia has the sixth highest incidence of T1D in the world.
- JDRF Australia dedicated $7.1 million to research and support programs in fiscal year 2014.
- In 2014, JDRF Canada invested $8.9 million in research, public education and advocacy.
- There are more than 300,000 Canadians living with T1D, and the rate of incidence is increasing each year.
- The JDRF Canadian Clinical Trial Network (CCTN) is currently funding 13 human and technological trials in Canada.
- JDRF Israel is the only nonprofit organization in Israel that is focused solely on people with T1D.
- Partnered with the Israel Science Foundation to establish a $6 million initiative to support T1D research in Israel.
- JDRF Israel serves approximately 50,000 people affected by T1D.
- JDRF Netherlands is the newest affiliate, founded in 2010.
- 150,000 people live with T1D in the Netherlands (total population 17 million).
- JDRF Netherlands supports five researchers in the Netherlands and two in Belgium.
- The UK has one of the highest rates of T1D in the world.
- Karen Addington, chief executive JDRF UK, was awarded UK Charity Leader of the Year 2015.
- Various world-leading T1D researchers are based at UK institutions, including Roman Hovorka, Ph.D., a JDRF-funded researcher working on artificial pancreas technology.